Netherton Syndrome Treatment Pipeline Analysis 2025

According to DelveInsight's evaluation, globally, the Netherton Syndrome pipeline comprises over 5 key pharmaceutical firms continuously advancing more than 5 Netherton Syndrome treatment therapies, with analysis of Clinical Trials, Therapeutics, Mechanism of Action, Route of Administration, and Developments conducted by DelveInsight.

"Netherton Syndrome Pipeline Analysis, 2025" report by DelveInsight outlines comprehensive intelligence into the current clinical development scenario and growth prospects across the Netherton Syndrome Market.

The Netherton Syndrome Pipeline analysis encompasses in-depth commercial and clinical evaluation of the pipeline products from the preclinical developmental phase to the marketed phase. The analysis also covers a comprehensive description of the medication, including the mechanism of action of the therapeutic, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Primary Highlights from the Netherton Syndrome Pipeline Analysis: https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

• Pharmaceutical firms across the globe are diligently advancing toward developing novel Netherton Syndrome treatment therapies with a considerable amount of success over recent years.

• Netherton Syndrome pharmaceutical firms operating in the treatment market include Quoin Pharmaceutical, Boehringer Ingelheim, LifeMax Laboratories, Novartis, Daiichi Sankyo, Quoin Pharmaceuticals, Children's Hospital of Philadelphia, among others, are creating therapies for Netherton Syndrome management.

• Emerging Netherton Syndrome investigational medications in the different phases of clinical trials include QRX003, SPEVIGO (spesolimab/BI 655130), LM-030 (BPR277), DS-2325a, Pimecrolimus, among others, are anticipated to have a significant impact on the Netherton Syndrome market in the forthcoming years.

• In October 2025, The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to QRX003, Quoin Pharmaceuticals' lead product candidate. Previously, the therapy received Orphan Drug Designation from the European Medicines Agency (EMA) in May and Rare Pediatric Disease (RPD) Designation in June. QRX003 is an innovative treatment for Netherton Syndrome.

• In September 2025, ResVita Bio, a biotechnology company advancing continuous protein therapy for skin disorders, revealed the successful completion of an in-person Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding RVB-003, its lead investigational therapy for Netherton Syndrome, a serious and chronic genetic skin condition.

• In June 2025, Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in innovative precision dermatology therapies, disclosed promising safety results from the initial clinical trial of its live biotherapeutic candidate, ATR12-351, for treating Netherton syndrome.

• In May 2025, Quoin Pharmaceuticals announced that it has received FDA clearance to initiate a second pivotal clinical trial for its investigational therapy QRX003, aimed at treating Netherton Syndrome (NS). This represents an important milestone as Quoin progresses its therapeutic candidate into late-stage clinical development.

• In April 2025, ResVita Bio, a therapeutics company specializing in skin disease treatments, revealed that the FDA has granted Orphan Drug Designation to RVB-003 for Netherton Syndrome, a serious and chronic skin disorder. Building on the FDA's earlier Rare Pediatric Disease Designation, this milestone highlights ResVita Bio's innovative continuous protein therapy platform, which delivers sustained drug levels directly to the skin, offering enhanced efficacy and improved safety compared to conventional topical treatments.

• In December 2024, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, disclosed that it has received FDA clearance to launch an additional clinical study of QRX003 for Netherton Syndrome (NS). QRX003 is a topical lotion formulated with a broad-spectrum serine protease inhibitor aimed at targeting the skin kallikreins responsible for the excessive skin shedding characteristic of this condition.

• In October 2024, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a clinical-stage specialty pharmaceutical company dedicated to rare and orphan diseases, revealed the expansion of its ongoing Netherton Syndrome (NS) clinical studies to include two additional international sites in the United Kingdom (UK). The newly added sites, Great Ormond Street Hospital and St. Thomas' Hospital in London, are renowned centers of excellence for treating Netherton Syndrome in the UK. Both facilities have patient cohorts that may be eligible to participate in Quoin's clinical trials.

Netherton Syndrome Background

Netherton syndrome is a rare genetic disorder distinguished by a triad of clinical features: ichthyosis (a skin condition that leads to dry, scaly skin), trichorrhexis invaginata (bamboo hair, where the hair shafts are fragile and can break easily), and atopic diathesis (a tendency to develop allergies such as asthma, hay fever, or eczema).

Access a Free Sample PDF Report to learn more about Netherton Syndrome Pipeline Therapeutic Evaluation- https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Emerging Netherton Syndrome Investigational Medications Under Different Phases of Clinical Development Include:

• QRX003: Quoin Pharmaceutical

• SPEVIGO (spesolimab/BI 655130): Boehringer Ingelheim

• LM-030 (BPR277): LifeMax Laboratories/Novartis

• DS-2325a: Daiichi Sankyo

• Pimecrolimus: Children's Hospital of Philadelphia

Netherton Syndrome Administration Method

The Netherton Syndrome pipeline analysis presents therapeutic evaluation of the pipeline medications by Administration Method. Products are classified under various administration routes, such as:

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Netherton Syndrome Molecular Classification

Netherton Syndrome products are classified under various molecular categories, such as:

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Netherton Syndrome Pipeline Therapeutics Evaluation

• Netherton Syndrome Evaluation by Product Category

• Netherton Syndrome By Stage and Product Category

• Netherton Syndrome Evaluation by Administration Method

• Netherton Syndrome By Stage and Administration Method

• Netherton Syndrome Evaluation by Molecular Classification

• Netherton Syndrome by Stage and Molecular Classification

DelveInsight's Netherton Syndrome Analysis covers approximately 5+ products under different phases of clinical development including:

• Late-phase products (Phase III)

• Mid-phase products (Phase II)

• Early-phase product (Phase I)

• Preclinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Administration Method

Further Netherton Syndrome product details are provided in the analysis. Access the Netherton Syndrome pipeline analysis to learn more about the emerging Netherton Syndrome therapies https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Major Pharmaceutical Firms in the Netherton Syndrome Therapeutics Market Include:

Key pharmaceutical firms developing therapies for Netherton Syndrome include Sixera Pharma Ab, Dermelix Biotherapeutics, Matrisys Bioscience, Lifemax Laboratories, Azitra Inc, Quoin Pharmaceuticals, Krystal Biotech, among others.

Netherton Syndrome Pipeline Analysis:

The Netherton Syndrome pipeline analysis offers intelligence into:

• The analysis delivers detailed intelligence regarding pharmaceutical companies developing therapeutics for Netherton Syndrome management, including cumulative therapies created by each organization for this indication.

• It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Netherton Syndrome Treatment.

• Netherton Syndrome key pharmaceutical firms engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) initiatives.

• Netherton Syndrome investigational medications classified by developmental phase, administration method, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular classification.

• Comprehensive analysis of partnerships (company-to-company collaborations and company-to-academia partnerships), licensing arrangements, and funding particulars for future progression of the Netherton Syndrome market.

The analysis is constructed using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, among others.

Access Sample PDF Report to learn more about Netherton Syndrome medications and therapies https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Netherton Syndrome Pipeline Market Strengths

• The pathogenesis basis of Netherton syndrome is well understood, with a definite link to mutations in the SPINK5 gene that have led to the discovery of potential pathways like IL-7 and KLK inhibition.

• Advocacy and support groups for Netherton syndrome are spreading awareness and providing a platform for medical experts, researchers, and patients to collaborate.

Netherton Syndrome Pipeline Market Opportunities

• IV immunoglobulin therapy in pediatrics has presented effective results, and continuous research in this area can lead to the development of disease-modifying therapies.

• Studies have demonstrated the potential of gene therapy in genodermatosis. Thus, developing therapies like replacement therapy and gene therapy can cure Netherton Syndrome.

Scope of Netherton Syndrome Pipeline Drug Intelligence

• Coverage: Global

• Key Netherton Syndrome Pharmaceutical Firms: Quoin Pharmaceutical, Boehringer Ingelheim, LifeMax Laboratories, Novartis, Daiichi Sankyo, Quoin Pharmaceuticals, Children's Hospital of Philadelphia, among others

• Key Netherton Syndrome Investigational Treatments: QRX003, SPEVIGO (spesolimab/BI 655130), LM-030 (BPR277), DS-2325a, Pimecrolimus, among others

• Netherton Syndrome Therapeutic Evaluation: Netherton Syndrome current marketed and Netherton Syndrome emerging therapies

• Netherton Syndrome Market Dynamics: Netherton Syndrome market drivers and Netherton Syndrome market obstacles

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us:

Kanishk

kkumar@delveinsight.com